MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "COMT inhibitors"

  • MDS Virtual Congress 2020

    Effect of opicapone and entacapone on daily pattern of motor fluctuations in Parkinson’s disease patients

    A. Lees, O. Rascol, J. Ferreira, O. Klepitskaya, M. Fonseca, D. Magalhães, J.F Rocha, P. Soares-da-Silva (London, United Kingdom)

    Objective: To evaluate the effect of opicapone (OPC) 50 mg versus entacapone (ENT) on daily pattern of motor fluctuations. Background: OPC, a once-daily catechol-O-methyltransferase inhibitor,…
  • MDS Virtual Congress 2020

    Efficacy and safety/tolerability of opicapone in catechol-O-methyltransferase inhibitor-naïve Parkinson’s disease patients recently diagnosed with motor fluctuations

    A. Lees, J. Ferreira, W. Poewe, H. Gama, D. Magalhães, J.F Rocha, P. Soares-da-Silva (London, United Kingdom)

    Objective: To evaluate the potential added benefit of opicapone (OPC), compared with placebo (PLC) and entacapone (ENT), in catechol-O-methyltransferase inhibitor (COMTi)-naïve Parkinson’s disease (PD) patients…
  • MDS Virtual Congress 2020

    Onset of Drug-Related Adverse Events in Parkinson’s Disease Patients with Motor Fluctuations Treated with Opicapone in Clinical Practice: OPTIPARK Post-Hoc Analysis

    A. Lees, H. Reichmann, J.F Rocha, D. Magalhães, P. Soares-da-Silva (London, United Kingdom)

    Objective: This post-hoc analysis investigated the onset of treatment-emergent adverse events (TEAEs) that were considered at least possibly related to opicapone (OPC) treatment. Background: OPC…
  • MDS Virtual Congress 2020

    Effect of opicapone and entacapone on levodopa short duration response

    P. LeWitt, J. Ferreira, G. Ebersbach, E. Tolosa, G. Liang, R. Loureiro, D. Magalhães, J.F Rocha, P. Soares-da-Silva (Detroit, MI, USA)

    Objective: To evaluate the effect of opicapone (OPC) 50 mg versus entacapone (ENT) on levodopa short duration response (SDR). Background: OPC, a once-daily catechol-O-methyltransferase inhibitor,…
  • MDS Virtual Congress 2020

    Levodopa Dose Equivalency for Opicapone and Safinamide

    J.C Martinez Castrillo, I. Parees Moreno, G. Sanchez Diez, E. Natera Villalba, A. Beltran Corbellini, A. García Plata, A. Alonso Cánovas (Madrid, Spain)

    Objective: To provide a levodopa dose equivalency (LED) for opicapone and safinamide. Background: Tomlinson at al., provided a schedule to calculate LED of the different…
  • MDS Virtual Congress 2020

    Opicapone and entacapone as add-on therapy to the treatment of infusions of levodopa-carbidopa intestinal gel in patients with advanced Parkinson’s disease

    J.C Martinez Castrillo, I. Parees Moreno, G. Sanchez Diez, A. Alonso Cánovas (Madrid, Spain)

    Objective: To study the effect of COMT inhibitors (opicapone and entacapone) in Parkinson's disease (PD) patients on levodopa-carbidopa intestinal gel (LCIG) and an insufficient control of…
  • MDS Virtual Congress 2020

    Efficacy of opicapone in different levodopa-containing treatment regimens in Parkinson’s disease patients with motor fluctuations

    A. Antonini, G. Ebersbach, O. Rascol, F. Ikedo, D. Magalhães, J.F Rocha, P. Soares-da-Silva (Padova, Italy)

    Objective: To evaluate the efficacy of opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuations being treated with different levodopa-containing treatment regimens. Background: OPC,…
  • MDS Virtual Congress 2020

    Opicapone management: A 2-year follow up real- life practice study

    M. Mata, C. Borrue, M. Almarcha (Madrid, Spain)

    Objective: The aim of this work is to show our clinical experience with opicapone in real practice in a cohort of 68 parkinsonian patients followed…
  • MDS Virtual Congress 2020

    Super-Responders to Opicapone Adjunct Treatment to Levodopa in Parkinson’s Disease Patients with Motor Fluctuations: Combined Post-Hoc Analysis of BIPARK-I and II

    A. Antonini, W. Poewe, J. Ferreira, G. Ebersbach, H. Gama, J.F Rocha, D. Magalhães, P. Soares-da-Silva (Padova, Italy)

    Objective: To evaluate the efficacy and safety of opicapone (OPC) in Parkinson’s disease (PD) patients who were considered ‘super-responders’ (>= 2 hours of OFF-time reduction…
  • MDS Virtual Congress 2020

    Opicapone in Clinical Practice in Parkinson’s Disease Patients with Motor Fluctuations: Findings from the OPTIPARK Study

    H. Reichmann, A. Lees, J.F Rocha, D. Magalhães, P. Soares-da-Silva (Dresden, Germany)

    Objective: This real-world study evaluated opicapone (OPC) 50-mg in a heterogeneous population of Parkinson’s disease (PD) patients treated in clinical practice. Background: OPC proved effective…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 11
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • #25116 (not found)
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley